CD274 and hepatocellular carcinoma: The CheckMate-040 study, a multicohort phase I-II trial of nivolumab in advanced HCC in both sorafenib naïve and experienced patients, was one of the key initial clinical studies to demonstrate a potential durable survival benefit in a proportion of patients, with responses seen regardless of HCC etiology or PD-L1 expression [30].